Genentech Sponsored Phase News Today

Genentech's Inavolisib Combination Reduces the Risk of Disease Progression by 57% in People With Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer With a PIK3CA Mutation

December 8, 2023

– Inavolisib in combination with palbociclib and fulvestrant more than doubled progression-free survival compared to palbociclib and fulvestrant alone –– The inavolisib combination has the potential to address resistance to treatment and poor prognosis associated with PIK3CA mutations –– These new data are being pre...

San Antonio United States South San Francisco Bruno Eschli Levi Garraway Loren Kalm

Source: pharmiweb.com

Navigation

Genentech Sponsored Phase News Today

Genentech's Inavolisib Combination Reduces the Risk of Disease Progression by 57% in People With Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer With a PIK3CA Mutation | National Business

Genentech's Inavolisib Combination Reduces the Risk of Disease Progression by 57% in People With Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer With a PIK3CA Mutation

Explore More Categories